0001127855-15-000307.txt : 20150720 0001127855-15-000307.hdr.sgml : 20150720 20150720121632 ACCESSION NUMBER: 0001127855-15-000307 CONFORMED SUBMISSION TYPE: DEF 14C PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150720 FILED AS OF DATE: 20150720 DATE AS OF CHANGE: 20150720 EFFECTIVENESS DATE: 20150720 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Enhance Skin Products Inc CENTRAL INDEX KEY: 0001395400 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] IRS NUMBER: 841724410 STATE OF INCORPORATION: NV FISCAL YEAR END: 0430 FILING VALUES: FORM TYPE: DEF 14C SEC ACT: 1934 Act SEC FILE NUMBER: 000-52755 FILM NUMBER: 15995458 BUSINESS ADDRESS: STREET 1: 695 SOUTH COLORADO BOULEVARD STREET 2: SUITE 480 CITY: DENVER STATE: CO ZIP: 80246 BUSINESS PHONE: (416) 644-8318 MAIL ADDRESS: STREET 1: 695 SOUTH COLORADO BOULEVARD STREET 2: SUITE 480 CITY: DENVER STATE: CO ZIP: 80246 FORMER COMPANY: FORMER CONFORMED NAME: ZEEZOO SOFTWARE CORP. DATE OF NAME CHANGE: 20070404 DEF 14C 1 ehskdef14c.htm ENHANCE SKIN PRODUCTS DEFINITIVE SCHEDULE 14C INFORMATION STATEMENT, 07.20.15 ehskdef14c.htm
UNITED STATES
SECURITES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14C

Information Statement Pursuant to Section 14(c)
of the Securities Exchange Act of 1934
 
x Filed by the Registrant   o Filed by a Party other than the Registrant
 
Check the appropriate box:
o    Preliminary Information Statement
o   Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2))
x    Definitive Information Statement
 
ENHANCE SKIN PRODUCTS INC.
(Name of Registrant as Specified In Its Charter)

Payment of Filing Fee (Check the appropriate box):
x   No fee required.
o    Fee computed on table below per Exchange Act Rules 14c-5(g) and Rule 0-11(a)(4).

1)
Title of each class of securities to which transaction applies:

2)
Aggregate number of securities to which transaction applies:
 
3)
Per unit price or other underlying value of transaction computer pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
 
4)
Proposed maximum aggregate value of transactions:

5)
Total fee paid:
 
  o Fee paid previously with preliminary materials.
  o
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously.  Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 
1)
Amount Previously Paid:

2)
Form, Schedule or Registration Statement No.:

3)
Filing Party:

4)
Date Filed:

ENHANCE SKIN PRODUCTS INC.
50 West Liberty Street, Suite 880
Reno, NV 80246

Registrant’s telephone number, including area code: (416) 306-2493
 
 
 
 
 
 
 
 
ENHANCE SKIN PRODUCTS INC.
50 West Liberty Street, Suite 880
Reno, NV 80246

NOTICE OF ACTIONS TO BE TAKEN PURSUANT TO WRITTEN CONSENT OF STOCKHOLDERS

WE ARE NOT ASKING YOU FOR A PROXY,
AND YOU ARE REQUESTED NOT TO SEND US A PROXY

To the Stockholders of Enhance Skin Products Inc.:

Notice is hereby given to holders of common stock, par value $0.001 per share of Enhance Skin Products Inc. (the "Company"), a Nevada corporation, of record at the close of business on the record date, July 7, 2015, pursuant to Rule 14c-2 promulgated under the Securities Exchange Act of 1934, as amended. This Information Statement is being furnished to such stockholders for the purpose of informing the stockholders in regards to the proposed amendment to the Company's articles of incorporation (the "Articles of Incorporation") to increase the Company's authorized capital stock from 300,000,000 shares of common stock with a par value of $0.001 to 600,000,000 shares of common stock with a par value of $0.001 per share.
 
Please note that this is not a request for your vote or a proxy statement, but rather an Information Statement designed to inform you of the amendments to our Articles of Incorporation.
 
We are not asking you for a proxy and you are requested not to send us a proxy.
 
SUMMARY OF PROPOSED AMENDMENT AND RELEVANT DATES
 
On July 3, 2015 our Board of Directors unanimously approved the amendment to our Articles of Incorporation (the "Articles of Amendment") to increase our authorized stock from 300,000,000 shares of common stock with a par value of $0.001 to 600,000,000 shares of common stock with a par value of $0.001 per share. Our Board of Directors has fixed the close of business on July 7, 2015 as the record date for the determination of stockholders who are entitled to receive this Information Statement. There were 101,017,882 shares of our common stock issued and outstanding on July 7, 2015.
 
Subsequent to our Board of Directors' approval of the amendment, on July 3, 2015, the holders of the majority of the outstanding shares of common stock of our Company provided written consent to the Articles of Amendment to our Articles of Incorporation. We will not file the Articles of Amendment to our Articles of Incorporation until at least 20 days after the filing and mailing of this Information Statement in definitive form. We anticipate that the definitive Information Statement will be mailed on or about July 18, 2015 to all stockholders of record as of the record date, and that the definitive Information Statement will be filed with the SEC on the same date. We anticipate that the Articles of Amendment to our Articles of Incorporation will be filed with the Nevada Secretary of State, and will become effective, on or about August 8, 2015.
 
The entire cost of furnishing this Information Statement will be borne by our Company. We will request brokerage houses, nominees, custodians, fiduciaries and other like parties to forward this Information Statement to the beneficial owners of our common stock held of record by them.
 
 
 
 
 
 
 
QUESTIONS AND ANSWERS

Q:   What actions were taken by written consent?
 
A:   We obtained stockholder consent for the amendment of our Articles of Incorporation to increase the amount of authorized shares of common stock of the Company, par value $0.001 per share, to 600,000,000.
 
Q:   How many shares of common stock were authorized as of July 3, 2015?
 
A:   On July 3, 2015, the date we received the consent of our majority stockholders for the amendment of our Articles of Incorporation, there were 101,017,882 authorized shares of common stock of the Company.

Q:   How many shares of common stock authorized as of July 3, 2015 has the Company reserved for issue?
 
A:   On July 3, 2015, the date we received the consent of our majority stockholders for the amendment of our Articles of Incorporation, the Company has either formally or informally reserved 113,094,379  shares of common stock it is obliged to issue, or has the option to issue under existing agreements. Not all of these common shares may be issued.

Q:   What vote was obtained to approve the increase in authorized shares of common stock?
 
A:   The Nevada Revised Statutes and our Amended and Restated Articles of Incorporation permit the approval of the increase in authorized shares of common stock by written consent of a majority of the Company’s stockholders. We obtained the approval of approximately 53.4% of our outstanding shares of voting capital stock that were entitled to give such consent.

Q:   Who is paying the cost of this Information Statement?
 
A:   We will pay for preparing, printing and mailing this Information Statement.

AMENDMENT TO THE COMPANY'S ARTICLES OF INCORPORATION
 
Our Articles of Incorporation authorize the issuance of 300,000,000 shares of common stock, $0.001 par value. On July 3, 2015, the Board of Directors approved an amendment to our Articles of Incorporation to increase the number of our authorized common stock to 600,000,000 shares, $0.001 par value.
 
As of the record date of July 7, 2015, we had 101,017,882 shares issued and outstanding. Stockholder approval for the amendment to our Articles of Incorporation was obtained by written consent of stockholders owning 53,910,239 shares of our common stock, which represented approximately 53.4% of our issued and outstanding common shares on the record date.
 
The proposed Articles of Amendment to our Articles of Incorporation are attached hereto as Schedule A. The Articles of Amendment will become effective when they are filed with the Nevada Secretary of State.
 
 
 
 
 
 
 
Reasons for the Increase in the Number of Authorized Shares of Common Stock
 
The purpose of increasing the Company's authorized stock to 600,000,000 shares of common stock is to enable the Board of Directors to have additional shares of common stock available to partially pay for services and effect transactions, including asset purchases to grow and expand the business and private placements to raise capital for our Company.
 
To date, the Company has issued shares in part payment for certain product development, marketing, business and financial planning and business development services. In order to conserve limited cash resources the Company anticipates entering similar arrangements in the future when it can on acceptable terms. The Company believes that such arrangements are not only financially beneficial to the Company but demonstrate the service provider’s belief and confidence in the Company and its products.
 
The Company is in discussions with several parties to acquire certain technology assets, including patents and patent applications, products and active ingredients, which are complementary to and synergistic with our existing patents, patent applications, current and future products and have the potential to expand and increase the attractiveness of our Visible Youth product lines to potential development and marketing partners. Given our limited cash resources the Company would seek to pay for such asset acquisitions primarily through the issue of shares and deferred consideration. There can be no assurances, however, that the Company’s efforts to acquire such assets on terms satisfactory to the Company, or at all will, be realized.
 
As at April 30, 2015 the Company had a working capital deficit of $608,832 and accumulated deficit of $2,422,260. The ability of the Company to continue as a going concern and become a profitable entity is dependent upon the Company’s successful efforts to obtain and continue to obtain additional funding to reposition and re-launch its product line and generate sales and then attain profitable operations.
 
On June 19, 2015, the Company issued a convertible promissory note in the amount of $43,000 to Vis Vires Group Inc. as disclosed in the Company’s 8K dated June 25, 2015. The note is due on March 23, 2016 and bears interest at 8% per annum. The loan becomes convertible 180 days after the date of the note. The loan and any accrued interest can then be converted into shares of the Company’s common stock at a rate of 58% multiplied by the market price, which is the average of the lowest three (3) trading prices for the common stock during the ten (10) trading day period ending on the latest complete trading day prior to the conversion date. During the first 180 days following the date of the note we have the right to prepay the principal and accrued but unpaid interest due under the note, together with any other amounts we may owe the holder under the terms of the note, at a graduating premium ranging from 120% to 145%. After this initial 180 day period, we do not have a right to prepay the note.

Additional financing will be required to reformulate the first two Visible Youth products; namely, the Visible Youth Repairing Serum and the Visible Youth Hydrating Moisturizer, and undertake two marketing clinical studies on these products, to pay on-going patent costs and to provide working capital prior to spending further sums on the further development of the remaining products and marketing materials. In the opinion of the Board these marketing studies will be necessary to obtain further funding on acceptable terms and to further discussions with licensing partners.  Further funding will be required to reformulate the remaining Visible Youth products, design and implement the consumer rebranding, manufacture prototypes, design and implement e-Commerce platforms, undertake additional marketing clinical studies, pay on-going patent costs and to provide working capital prior to market launch.
 
 
 
 
 
 
 
Further funding will also be required to fund its market launch and direct to consumer sales campaign. The amount of funding required will depend on whether the Company decides to build its own US consumer marketing structure or to out-license to a marketing partner. The Board intends to evaluate the alternative marketing strategies for the US consumer market upon completion of the clinical studies.
 
The Company is consequently pursuing a number of funding structures including debt and equity finance, asset sales, licensing and partnering activities and may issue further convertible promissory notes. The Company may also seek alternative funding to repay the existing convertible promissory note should that prove beneficial. There can be no assurances, however, that management’s efforts to obtain additional funding and licensing or marketing partners on terms satisfactory to the Company, or at all will, be realized or that future sales will be realized.
 
Our Board of Directors therefore believes that it is in the best interests of our Company to increase its number of authorized shares of common stock for such purposes.
 
The increased number of authorized shares of common stock will be available for issuance from time to time for such purposes and consideration as the Board of Directors of the Company may approve and no further approval by our stockholders will be required, except as provided under Nevada law or under the rules of any national securities exchange or market on which our common stock may in the future be listed. The Company intends to attempt to partially pay for services to be provided to the Company, to seek asset purchases, and equity financing which would result in the issue of the additional shares that will become authorized share capital of the Company pursuant to the proposed increase in authorized share capital described herein.
 
The increase in authorized common stock will not have any immediate effect on the rights of our existing stockholders. To the extent that additional authorized shares are issued in the future, they would decrease our existing stockholders’ percentage equity ownership in the Company and, depending on the price at which they are issued, may be dilutive to existing stockholders. The additional shares of common stock have identical rights, preferences and privileges to the shares of our common stock authorized prior to approval of this action.
 
Anti-Takeover Effects of the Proposed Amendment
 
Although the Company has no present intention or plan to employ the additional unissued authorized shares as an anti-takeover device, it is possible that management could use the additional shares to resist or frustrate a third-party transaction providing an above-market premium that is favored by a majority of the independent stockholders. For example, shares of authorized and unissued common stock could (within the limits imposed by applicable law) be issued in one or more transactions that would discourage persons from attempting to gain control of the Company, by diluting the voting power of shares then outstanding. Similarly, the issuance of additional shares to certain persons allied with the Company's management could have the effect of making it more difficult to remove the Company's current management by diluting the stock ownership or voting rights of persons seeking to cause such removal. Each of these could potentially limit the opportunity for the Company's stockholders to dispose of their stock at a premium.
 
The Board of Directors is not aware of any attempt, or contemplated attempt, to acquire control of the Company, and the proposed Articles of Amendment to the Company's Articles of Incorporation to increase the number of authorized shares of common stock is not being proposed with the intention that it be utilized as a type of anti-takeover device or to secure management's positions within the Company.
 
 
 
 
 
 
 
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
 
As of the record date, July 7, 2015, we had a total of 101,017,882 shares of common stock, $0.001 par value per share, issued and outstanding.
 
The following table sets forth, as of the record date of July 7, 2015, certain information with respect to the beneficial ownership of our common stock by each stockholder known by us to be the beneficial owner of more than 5% of our common stock and by each of our current directors and executive officers. Each person has sole voting and investment power with respect to the shares of common stock, except as otherwise indicated. Beneficial ownership consists of a direct interest in the shares of common stock, except as otherwise indicated. Unless otherwise indicated, each person has an address c/o Enhance Skin Products Inc., 50 West Liberty Street, Suite 880, Reno, NV 80246.

Name of Beneficial Owner
  
Common Stock Beneficially
Owned(1)
    
Percent of
Class
  
Biostrategies Consulting Group Inc.(2)
     8,015,834       7.9 %
Samuel Asculai(3)
     32,419,105       32.1 %
Frode Botnevik(4)
     3,324,468       3.3 %
Mercuriali Ltd.(5)
     9,000,000       8.9 %
Donald Nicholson(6)
     9,000,000       8.9 %
Drasko Puseljic
     9,166,666       9.1 %
Directors and executive officers as a group (4 persons)
     18,333,334       53.4 %
Christopher Hovey
     8,628,670       8.5 %
 
(1)
Information relating to beneficial ownership of common stock by our principal shareholders and management is based upon information furnished by each person using “beneficial ownership” concepts under the rules of the Securities and Exchange Commission.  Pursuant to these rules, a person is deemed to be a beneficial owner of a security if that person has or shares voting power, which includes the power to vote or direct the voting of the security, or investment power, which includes the power to vote or direct the voting of the security.  The person is also deemed to be a beneficial owner of any security of which that person has a right to acquire beneficial ownership within 60 days.  Pursuant to the Securities and Exchange Commission rules, more than one person may be deemed to be a beneficial owner of the same securities, and a person may be deemed to be a beneficial owner of securities as to which he or she may not have any pecuniary beneficial interest.  Except as specified otherwise, each person has sole voting and investment power.
(2)
Samuel Asculai, who is a director and officer of the Company, is the sole owner of Biostrategies Consulting Group Inc.
(3)
Common stock beneficially owned by Samuel Asculai includes the 8,015,834 shares of Common Stock owned by Biostrategies Consulting Group Inc. reported in this table.
(4)
Common Stock Beneficially Owned by Frode Botnevik includes 3,324,468 shares of Common Stock owned by Grim AS a company controlled by his spouse.
(5)
Mercuriali Ltd. is controlled by Donald Nicholson, who is a director and officer of the Company.
(6)
Common stock beneficially owned by Donald Nicholson includes the 9,000,000 shares of Common Stock owned by Mercuriali Ltd. reported in this table.

 
 
 
 
 

 
DESCRIPTION OF THE COMPANY

The Company is a developer of cosmeceutical products marketed using its Visible Youth trademark. Cosmeceuticals are topically applied products containing ingredients that influence the biological function of skin and can be described as a combination of cosmetics and pharmaceuticals. These products may improve the appearance and condition of the skin by delivering nutrients or protectants necessary for healthy skin.  

The Company was originally incorporated as Zeezoo Software Corp. (“Zeezoo”) under the laws of the state of Nevada on November 14, 2006.  On August 14, 2008, the Company acquired all of the intellectual property and certain liabilities of a privately owned Ontario corporation (“Enhance Private”) pursuant pursuant to an Asset Purchase Agreement.  In addition to shares issued for the asset purchase and the cancellation of certain securities of the Company, Enhance Private acquired approximately 57.6% of the issued and outstanding shares of common stock of the Company.  On August 28, 2008, the Company changed its name to Enhance Skin Products Inc.

Our principal offices are located at 50 West Liberty Street, Suite 880, Reno, NV 80246, (416) 306-2493.
 
DISSENTER'S RIGHTS

Under Nevada law stockholders are not entitled to dissenter's rights of appraisal with respect to our Company's proposed Articles of Amendment to its Articles of Incorporation, and we will not independently provide our stockholders with any such rights.
 
DELIVERY OF DOCUMENTS TO
SECURITY HOLDERS SHARING AN ADDRESS

One Information Statement will be delivered to multiple stockholders sharing an address unless the Company receives contrary instructions from one or more of the stockholders sharing such address. Upon receipt of such notice, the Company will undertake to promptly deliver a separate copy of this Information Statement to the stockholder at the shared address to which a single copy of this Information Statement was delivered and provide instructions as to how the stockholder can notify us that the stockholder wishes to receive a separate copy of this Information Statement or other communications to the stockholder in the future. In the event a stockholder desires to provide us with such notice, it may be given verbally by telephoning the Company's offices at (416) 306-2493 or by mail to the Company's address at 50 West Liberty Street, Suite 880, Reno, NV 80246.

ADDITIONAL INFORMATION

The Company files annual, quarterly and special reports, proxy statements and other information with the SEC. The periodic reports and other information that the Company has filed with the SEC, may be inspected and copied at the SEC's Public Reference Room at 100 F Street, N.E., Washington, DC, U.S.A., 20549. You may obtain information as to the operation of the Public Reference Room by calling the SEC at 1-800-SEC- 0330. The SEC also maintains a web site that contains reports, proxy statements and other information about issuers, like the Company, who file electronically with the SEC. The address of that site is www.sec.gov.
 
 
 By Order of the Board of Directors  
     
  /s/ Donald Nicholson  
  Donald Nicholson  
  CEO, Chief Financial Officer and Principal Executive Officer  
 
 
 
 
 
 
 

Schedule A
 
CERTIFICATE OF AMENDMENT
 
Certificate of Amendment to Articles of Incorporation
For Nevada Profit Corporation
(Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock)
 
1.Name of corporation:
 
Enhance Skin Products Inc.
 
2.The Articles of Incorporation have been amended as follows (provide article numbers, if available):
 
3.
The authorized capital stock of the Corporation will consist of six hundred million (600,000,000) shares of common stock, par value $0.001 per share.
 
3.The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation* have voted in favor of the amendment is: 53.4%.
 
4.Effective date of filing (optional):
 
5.Officer Signature (required):
 
X________________________________________
Signature of Officer
 
*If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote, in addition to the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power of each class or series affected by the amendment regardless of limitations or restrictions on the voting power thereof.
__________